SCHEMBL1662688

SCHEMBL1662688

CC(C)(C)OC(=O)N1CCN(c2ccc(F)c(CO)c2F)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.48
MAPT P10636 3/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM1A O60341 1/20 0.42
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665283 0.85 GPR119 (0.48) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL1665432 0.84 GPR119 (0.46) GPR119MAPTALDH1A1LMNAMEN1
SCHEMBL1663232 0.81 MAPT (0.46) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL31651685 0.81 MAPT (0.46) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL29471910 0.81 MAPT (0.46) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL8220970 0.80 SMN1; SMN2 (0.47) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL8250638 0.80 L3MBTL1 (0.52) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL670559 0.80 ACHE (0.48) GPR119MAPTALDH1A1LMNAMEN1
SCHEMBL21995951 0.79 MAPT (0.49) GPR119MAPTALDH1A1LMNAL3MBTL1
SCHEMBL12957576 0.79 TP53 (0.51) GPR119MAPTALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 GPR119 3906/4885MAPT 4393/4885ALDH1A1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.